Russell Alan J - Sep 23, 2021 Form 4 Insider Report for Edgewise Therapeutics, Inc. (EWTX)

Role
Chief Scientific Officer, Director
Signature
/s/ John R. Moore, Attorney-in-Fact for Russell Alan J
Stock symbol
EWTX
Transactions as of
Sep 23, 2021
Transactions value $
-$1,071,422
Form type
4
Date filed
9/27/2021, 07:32 PM
Previous filing
Aug 19, 2021
Next filing
Sep 30, 2021

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction EWTX Common Stock Sale -$399K -21.8K -8.24% $18.34 242K Sep 23, 2021 Direct F1, F2
transaction EWTX Common Stock Sale -$98.5K -5.07K -2.09% $19.42 237K Sep 23, 2021 Direct F3
transaction EWTX Common Stock Sale -$365K -20.1K -8.47% $18.16 217K Sep 24, 2021 Direct F4
transaction EWTX Common Stock Sale -$208K -11.6K -5.34% $17.98 206K Sep 27, 2021 Direct F5
transaction EWTX Common Stock Sale -$314 -17 -0.01% $18.48 206K Sep 27, 2021 Direct
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 Plan adopted by the Reporting Person on June 17, 2021.
F2 The price reported in column 4 is an average price. These shares were sold in multiple transactions at prices ranging from $17.93 to $18.925, inclusive. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F3 The price reported in column 4 is an average price. These shares were sold in multiple transactions at prices ranging from $18.97. to $19.96, inclusive. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F4 The price reported in column 4 is an average price. These shares were sold in multiple transactions at prices ranging from $17.84 to $18.45, inclusive. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F5 The price reported in column 4 is an average price. These shares were sold in multiple transactions at prices ranging from $17.47 to $18.45, inclusive. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.